



GAGNANTS DE LA BOURSE DR ANDREW R. BELCH POUR ENCOURAGER L'ÉDUCATION ET LA FORMATION CONTINUE DE JEUNES CHERCHEURS DANS LE DOMAINE DU MYÉLOME (EFCM)

2019

- **Dre Eva Laverdure** – Clinical and Prognostic Impact of Circulating Plasma Cells on Peripheral Blood Smears in Multiple Myeloma at Presentation and During Follow-up
- **Dre Hannah Cherniawsky** – The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting
- **Dre Bethany Monteith Ames** – Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with Highdose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)
- **Aline Rangel Pozzo** – The Three Dimensional (3D) Spatial Distribution of Lamin A/C in the Nuclei of Myeloma Cells

2022

- **Dr Jean-Sébastien Claveau** – Bortezomib Maintenance after Upfront Allogeneic Transplantation in Myeloma Patients: Less Chronic GVHD and Immunosuppression but Still No Impact on Survival
- **Dre Holly Lee** – Point Mutations in BCMA Extracellular Domain Mediate Resistance to BCMA Targeting Immune Therapies
- **Dre Alissa Visram** – The Impact of Marginalization on Treatment Receipt and Overall Survival in Newly Diagnosed Multiple Myeloma Patients in Ontario: A Population-based Cohort Study
- **Afsaneh Panahi** – Identification of Misclassified Multiple Myeloma Patient Risk Subgroups with a Novel Biological Disease Stratifier
- **Samantha Fowler** – Moving from Research Priorities to Clinical Research: Implementing the Results of a Priority Setting Partnership on Multiple Myeloma
- **Dr Guido Lancman** – Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies